drugset
drugset / Trial / NCT02387294

Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents

NCT02387294 ↗

Phase 3 Completed 120 enrolled Fluart Innovative Vaccine Ltd, Hungary
Non-randomizedSingle-groupOpen-labelPrevention

Summary

Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (trivalent, seasonal influenza vaccine, active ingredient content: 6 μg HA/strain/0.5 ml) for Children and Adolescents.

Timeline

Start
2014-10
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluval AB Novo Vaccine 0.25 ml Intramuscular
Subject Fluval AB Novo Vaccine 0.5 ml Intramuscular

Indications

influenza